[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351374-105":59,"doc-detail-351374-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","metformin-drives-hif-1-mediated-dual-metabolic-reprogramming-to-enhance-t-cell-therapy-in-triple-negative-breast-cancer","Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer","","Triple-negative breast cancer (TNBC) lacks effective targeted options, making γδ T cell immunotherapy a promising strategy despite frequent limitations from exhaustion and immunosuppression. The study tested whether metformin enhances γδ T cell–mediated anti-TNBC immunity. Metformin increased cytotoxicity, proliferation, and cytokine output while reducing exhaustion markers, and reprogrammed immune-cell metabolism via AMPK-HIF1-α–linked enhancement of OXPHOS and glycolysis with reciprocal suppression in cancer cells. It also upregulated tumor stress ligands and restored γδ T cell function in chemoresistant models, with clinical data linking AMPK activity and γδ T cell infiltration to improved survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metformin-drives-hif-1-mediated-dual-metabolic-reprogramming-to-enhance-t-cell-therapy-in-triple-negative-breast-cancer/351374/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metformin-drives-hif-1-mediated-dual-metabolic-reprogramming-to-enhance-t-cell-therapy-in-triple-negative-breast-cancer/351374.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does metformin affect γδ T cells in the TNBC model?","Question",{"text":112,"@type":113},"Metformin increases γδ T cell cytotoxicity, proliferation, and cytokine production while reducing exhaustion markers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What metabolic mechanism links metformin to dual reprogramming?",{"text":117,"@type":113},"Metformin modulates cellular metabolism through AMPK-HIF1-α signaling, enhancing OXPHOS and glycolysis in γδ T cells while suppressing these pathways in cancer cells.",{"name":119,"@type":110,"acceptedAnswer":120},"Is metformin beneficial in chemoresistant settings and what do clinical data suggest?",{"text":121,"@type":113},"In chemoresistant models, metformin restores γδ T cell function. Clinical data associate high AMPK activity and increased γδ T cell infiltration with improved patient survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351374,1790133645,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Cancer Immunology, Immunotherapy (2026) 75:133  \n[https://doi.org/10.1007/s00262-026-04351-w](https://doi.org/10.1007/s00262-026-04351-w)  \nMetformin drives HIF‑1α–mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple‑negative breast cancer  \nXuping Qin1 · Haowen Zhong1 · Meize Liu1 · TiantianYu1 · Rong Ma1 · Ying Zhou1 · Jingyu Chen1 · Fen Liu2 · Xiwei Wang1 · Jianting Long1  \nReceived: 27 September 2025 / Accepted: 24 February 2026 © The Author(s) 2026  \nAbstract  \nTriple-negative breast cancer (TNBC) lacks effective targeted treatments, rendering γδ T cell immunotherapy a promising therapeutic strategy. However, the function of these immune cells is often limited by exhaustion and immunosuppression. This study investigated whether metformin can enhance γδ T cell-mediated immunity against TNBC. Results demonstrated that metformin increased the cytotoxicity, proliferation, and cytokine production of γδ T cells while reducing their exhaustion markers. It differentially modulated cellular metabolism by enhancing oxidative phosphorylation (OXPHOS) and glycolysis in γδ T cells while suppressing these pathways in cancer cells through AMPK-HIF1-α signaling. Metformin also upregulated stress ligands on tumor cells, thereby improving immune recognition. In chemoresistant models, metformin restored γδ T cell function. Clinical data further showed that high AMPK activity and increased γδ T cell infiltration were associated with improved patient survival. These findings indicate that metformin remodels immunometabolism and enhances tumor immunogenicity, supporting its potential as a combinatory agent in γδ T cell-based immunotherapy for TNBC.  \nKeywords Metformin · γδ T cells · TNBC · Metabolic reprogramming  \nIntroduction  \nTriple-negative breast cancer (TNBC) is defined as a unique breast cancer subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [1] . This aggressive malignancy comprises 12–20% of breast cancer cases and demonstrates worse clinical outcomes than other subtypes [2, 3] . TNBC typically exhibits high histological grade, rapid proliferation kinetics, and elevated  \nXuping Qin, Haowen Zhong and Meize Liu have contributed equally.  \n* Xiwei Wang [wangxw83@mail.sysu.edu.cn](wangxw83@mail.sysu.edu.cn)  \n* Jianting Long [longjt2@mail.sysu.edu.cn](longjt2@mail.sysu.edu.cn)  \n1 Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China  \n2 Department of Gastroenterology and Hepatology, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China  \nrisk of early recurrence, with most events occurring within 3–5 years after diagnosis [2, 4].The disease exhibits a predilection for visceral metastases, particularly to the lungs and brain, distinguishing it from other breast cancer variants. Without therapeutic targets for endocrine or HER2-directed agents, systemic chemotherapy remains the cornerstone of TNBC management [5] .  \nIn recent years, immunotherapy has transformed cancer treatment paradigms. Immune checkpoint inhibitors (ICIs), such as agents targeting PD-1/PD-L1, demonstrated tumor regression in select TNBC patients, as evidenced by clinical trials [6, 7] . The KEYNOTE-522 trial further established pembrolizumab combined with chemotherapy as an effective regimen for early-stage TNBC [8, 9] . Adoptive cell therapy (ACT) has similarly shown therapeutic potential, with tumor-infiltrating lymphocyte (TIL) transfer mediating objective responses in metastatic breast cancer patients during preliminary investigations [10, 11] . These immunotherapeutic approaches collectively represent significant progress in TNBC management, with continued research likely to yield further improvements.  \nγδ T cells constitute a distinct lymphocyte population that contributes substantially to antitumor immunity.  \nUnlike con","cbCailgWwR6092Ly","https://ap.wps.com/l/cbCailgWwR6092Ly","pdf",6190518,"English","# Abstract\n# Keywords\n# Introduction\n## TNBC background and current treatment landscape\n## Immunotherapy advances in TNBC\n## Biology and therapeutic rationale of γδ T cells\n## Metformin’s anti-tumor and immunomodulatory roles","[{\"question\":\"How does metformin affect γδ T cells in the TNBC model?\",\"answer\":\"Metformin increases γδ T cell cytotoxicity, proliferation, and cytokine production while reducing exhaustion markers.\"},{\"question\":\"What metabolic mechanism links metformin to dual reprogramming?\",\"answer\":\"Metformin modulates cellular metabolism through AMPK-HIF1-α signaling, enhancing OXPHOS and glycolysis in γδ T cells while suppressing these pathways in cancer cells.\"},{\"question\":\"Is metformin beneficial in chemoresistant settings and what do clinical data suggest?\",\"answer\":\"In chemoresistant models, metformin restores γδ T cell function. Clinical data associate high AMPK activity and increased γδ T cell infiltration with improved patient survival.\"}]","Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer | PDF",1790093877,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31446509cb3a4cd55930496b9d68c927.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54c4a05485d9560630e33533d0cb44a4.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e29519bcc44d1c5af52434bdbced59e.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ba220af326c70960a07e4b8f0bb64bf.webp",980,1301]